Repro Med Systems, Inc. dba KORU Medical System develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings.
Company profile
Ticker
KRMD
Exchange
Website
CEO
Donald B. Pettigrew
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
REPRO MED SYSTEMS INC
SEC CIK
Corporate docs
IRS number
133044880
KRMD stock data
Latest filings (excl ownership)
EFFECT
Notice of effectiveness
1 Jun 23
S-3/A
Shelf registration (amended)
26 May 23
S-3
Shelf registration
17 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
17 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
17 May 23
8-A12B/A
Registration of securities on exchange (amended)
17 May 23
8-K
Entry into a Material Definitive Agreement
17 May 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Koru Medical Systems, Inc. Announces 2023 First Quarter Financial Results
4 May 23
DEF 14A
Definitive proxy
29 Mar 23
Transcripts
KRMD
Earnings call transcript
2022 Q4
8 Mar 23
KRMD
Earnings call transcript
2022 Q3
12 Nov 22
KRMD
Earnings call transcript
2022 Q2
7 Aug 22
KRMD
Earnings call transcript
2022 Q1
8 May 22
KRMD
Earnings call transcript
2021 Q4
3 Mar 22
KRMD
Earnings call transcript
2021 Q3
11 Nov 21
KRMD
Earnings call transcript
2021 Q2
12 Aug 21
KRMD
Earnings call transcript
2021 Q1
12 May 21
KRMD
Earnings call transcript
2020 Q4
24 Mar 21
KRMD
Earnings call transcript
2020 Q3
4 Nov 20
Latest ownership filings
Financial summary
| Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 12.22 mm | 12.22 mm | 12.22 mm | 12.22 mm | 12.22 mm | 12.22 mm |
| Cash burn (monthly) | 1.73 mm | 862.70 k | 1.02 mm | 892.60 k | 1.55 mm | 692.76 k |
| Cash used (since last report) | 3.84 mm | 1.92 mm | 2.26 mm | 1.98 mm | 3.45 mm | 1.54 mm |
| Cash remaining | 8.39 mm | 10.31 mm | 9.96 mm | 10.24 mm | 8.77 mm | 10.69 mm |
| Runway (months of cash) | 4.9 | 11.9 | 9.8 | 11.5 | 5.6 | 15.4 |
Institutional ownership, Q4 2022
59.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 40 |
| Opened positions | 6 |
| Closed positions | 3 |
| Increased positions | 13 |
| Reduced positions | 6 |
| 13F shares | Current |
|---|---|
| Total value | 56.01 bn |
| Total shares | 27.34 mm |
| Total puts | 100.00 |
| Total calls | 3.40 k |
| Total put/call ratio | 0.0 |
| Largest owners | Shares | Value |
|---|---|---|
| Horton Capital Partners | 10.74 mm | $37.49 mm |
| First Light Asset Management | 6.34 mm | $22.63 bn |
| Archon Capital Management | 2.97 mm | $10.60 bn |
| Vanguard | 1.35 mm | $4.81 bn |
| 272 Capital | 904.03 k | $3.23 bn |
| Albion Financial | 876.45 k | $3.13 bn |
| Altium Capital Management | 855.00 k | $3.05 bn |
| Parkman Healthcare Partners | 723.06 k | $2.58 bn |
| Meros Investment Management | 432.85 k | $1.55 mm |
| BLK Blackrock | 345.29 k | $1.23 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar 23 | Beck James M | Common Stock | Grant | Acquire A | No | No | 4.26 | 3,521 | 15.00 k | 87,860 |
| 31 Mar 23 | Robert Cascella | Common Stock | Grant | Acquire A | No | No | 4.26 | 3,521 | 15.00 k | 17,971 |
| 31 Mar 23 | Fletcher R John | Common Stock | Grant | Acquire A | No | No | 4.26 | 5,281 | 22.50 k | 140,380 |
| 31 Mar 23 | Donna French | Common Stock | Grant | Acquire A | No | No | 4.26 | 3,521 | 15.00 k | 37,330 |
| 31 Mar 23 | Shahriar Matin | Common Stock | Grant | Acquire A | No | No | 4.26 | 3,521 | 15.00 k | 40,753 |
News
KORU Medical Systems Q1 Adj EPS $(0.05), Inline, Sales $7.39M Miss $7.44M Estimate
4 May 23
KORU Medical Systems Q1 EPS $(0.05), Inline, Sales $7.39M Miss $7.44M Estimate
4 May 23
Earnings Scheduled For May 4, 2023
4 May 23
Repro-Med Systems's Return On Capital Employed Overview
10 Mar 23
Repro-Med Systems Q4 EPS $(0.04) Beats $(0.06) Estimate, Sales $7.34M Miss $7.38M Estimate
8 Mar 23